Evaluation of the Effectiveness of the BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Circumferential Reduction
- Sponsor
- BTL Industries Ltd.
- Enrollment
- 102
- Locations
- 1
- Primary Endpoint
- Waist Circumference Reduction
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Prospective, two-arm, randomized study of the effectiveness of the BTL-9000 HFT in achieving 3 cm or greater average waist circumferential reduction in HFT group of subjects relative to the base line and 1 cm or greater reduction relative to the average waist circumferential reduction of the Placebo group.
Detailed Description
Prospective, randomized, blinded, two-arms study of waist circumferential reduction following 5 once-a-week treatments. One arm is the HFT group of 64 subjects who are treated with the BTL-9000 HFT and the other arm is the Placebo group of 38 subjects treated with the sham device. The objective of the study is to demonstrate the effectiveness of the BTL-9000 HFT treatment in achieving average post-treatment waist circumference reduction of 3 cm or greater across the waistline relative to the baseline assessment and of 1 cm or greater than the average waist circumferential reduction of the Placebo group.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects 18-70 years of age of both gender with excess adipose tissue in the abdomen area
- •Body Mass Index (BMI) of 25 to 35 kg/m
- •Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation.
- •Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation.
Exclusion Criteria
- •- Diabetics dependent on insulin or oral hypoglycemic medications
- •Known cardiovascular disease such as arrhythmias, congestive heart failure
- •Cardiac surgeries such as cardiac bypass, heart transplant surgery, pacemakers.
- •Implanted electronic device such as a cardiac pacemaker, bladder stimulator, spinal cord stimulator or electrodes for a myoelectric prosthesis, etc.
- •Prior surgical interventions for body sculpting of abdomen such as liposuction
- •Medical, physical or other contraindications for body sculpting/ weight loss
- •Current use of medication known to affect weight levels and/or cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent
- •Any medical condition known to affect weight levels and/or to cause bloating or swelling
- •Active infection, wound or other external trauma to the area to be treated
- •Pregnant, breast feeding, or planning pregnant before the end of the study
Outcomes
Primary Outcomes
Waist Circumference Reduction
Time Frame: 1 month follow up after 5 once-a-week treatments
The subjects in the HFT group whose average post-treatment waist circumference shows reduction of 3 cm or greater across the waistline relative to the base line assessment and their mean waist circumferential reduction is 1 cm or greater than the average circumferential reduction of Placebo group are considered to meet the study primary outcome success criteria.
Secondary Outcomes
- Adverse Events(1 month follow up)